A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

NCT ID: NCT07011745

This clinical trial, called ADAGIO-2, is investigating a new treatment called KarXT + KarX-EC for adults with Alzheimer's disease who experience agitation. Agitation can include feelings of restles...

Recruiting

Phase: PHASE3 Conditions: Alzheimer Disease

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT ID: NCT03486873

This clinical trial, called MK-3475-587, is looking into the long-term safety and effectiveness of a treatment called pembrolizumab (also known as MK-3475) for patients with advanced tumors. If you...

Recruiting

Phase: PHASE3 Conditions: Solid Tumors, Hematologic Malignancies

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT ID: NCT06937229

The ADAGIO-3 study is a clinical trial focused on testing a new treatment for agitation in people with Alzheimer’s Disease. This trial will specifically look at the long-term effects and safety of ...

Not yet recruiting

Phase: PHASE3 Conditions: Alzheimer Disease, Agitation

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

NCT ID: NCT06140836

The TRIDENT-3 clinical trial is studying two medications, repotrectinib and crizotinib, to see how effective and safe they are for treating patients with a specific type of lung cancer called ROS1-...

Recruiting

Phase: PHASE3 Conditions: Carcinoma, Non-Small-Cell Lung

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

NCT ID: NCT06976203

The MINDSET 2 clinical trial is a research study designed to test a new treatment called KarXT combined with KarX-EC for people with cognitive impairment due to Alzheimer's disease. This study aims...

Recruiting

Phase: PHASE3 Conditions: Alzheimer's Disease

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT ID: NCT06136650

This clinical trial is studying a new medication called opevesostat (MK-5684) to see how well it works when combined with hormone replacement therapy (HRT) for men with metastatic castration-resist...

Recruiting

Phase: PHASE3 Conditions: Prostatic Neoplasms, Metastatic Castration-resistant Prostate Cancer (mCRPC)

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT ID: NCT06305754

This clinical trial is studying a new treatment called sacituzumab tirumotecan to see how it compares to a standard combination of two existing drugs, pemetrexed and carboplatin, for patients with ...

Recruiting

Phase: PHASE3 Conditions: Non-small Cell Lung Cancer (NSCLC)

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT ID: NCT06356129

This clinical trial is studying a new treatment for patients with a type of cancer called high-risk large B-cell lymphoma (LBCL). Researchers want to see if adding a medication called golcadomide t...

Recruiting

Phase: PHASE3 Conditions: Large B-cell Lymphoma

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT ID: NCT06459180

This clinical trial is studying a treatment called sacituzumab tirumotecan for women with recurrent or metastatic cervical cancer, which means the cancer has come back or spread after initial treat...

Recruiting

Phase: PHASE3 Conditions: Cervical Cancer

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

NCT ID: NCT06481306

This clinical trial is studying a new medication called BMS-986470 to see how safe it is and how well it works for people with sickle cell disease and healthy volunteers. The researchers want to un...

Recruiting

Phase: PHASE1 Conditions: Healthy Volunteers, Anemia, Sickle Cell

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT ID: NCT07100080

This clinical trial is studying a new drug called Izalontamab Brengitecan to see how well it works compared to a standard chemotherapy treatment (platinum-pemetrexed) for people with a specific typ...

Not yet recruiting

Phase: PHASE2 Conditions: Non-Small Cell Lung Cancer

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

NCT ID: NCT06077760

This clinical trial is looking at a new treatment combination for patients with non-small cell lung cancer (NSCLC) who have had surgery to remove their cancer. The study compares the effects of a d...

Recruiting

Phase: PHASE3 Conditions: Non-small Cell Lung Cancer

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT ID: NCT04924075

This clinical trial is studying a new treatment called belzutifan for patients with certain advanced tumors, including pheochromocytoma, paraganglioma, pancreatic neuroendocrine tumors, and other s...

Recruiting

Phase: PHASE2 Conditions: Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease +3 more

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

NCT ID: NCT05748171

This clinical trial is studying a medication called Inotuzumab Ozogamicin (InO) to see how well it works for children and teenagers aged 1 to under 18 who have a type of leukemia called acute lymph...

Recruiting

Phase: PHASE2 Conditions: ACUTE LYMPHOBLASTIC LEUKEMIA

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

NCT ID: NCT05869955

This clinical trial is investigating a new treatment called CC-97540, which uses special immune cells (CAR T cells) designed to target a protein involved in certain autoimmune diseases. The goal of...

Recruiting

Phase: PHASE1 Conditions: Rheumatoid Arthritis, Systemic Lupus Erythematosus +2 more

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

NCT ID: NCT05617677

This clinical trial is studying a medication called deucravacitinib to see how well it works and how safe it is for people with moderate to severe Systemic Lupus Erythematosus (SLE), a condition th...

Recruiting

Phase: PHASE3 Conditions: Systemic Lupus Erythematosus

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

NCT ID: NCT06492616

This clinical trial is studying a new medication called elacestrant to see how well it works compared to standard hormonal treatments in women and men with early-stage breast cancer that is hormone...

Recruiting

Phase: PHASE3 Conditions: Breast Cancer

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

NCT ID: NCT06551324

This clinical trial, called MEVPRO-1, is looking at a new medicine called PF-06821497 (Mevrometostat) to see if it can help men with metastatic castrate-resistant prostate cancer (mCRPC) who have p...

Recruiting

Phase: PHASE3 Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC)

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

NCT ID: NCT06629779

This clinical trial is studying a new drug called PF-06821497 (also known as Mevrometostat) to see if it works better when combined with another medication called enzalutamide for men with metastat...

Recruiting

Phase: PHASE3 Conditions: Metastatic Castration-Resistant Prostate Cancer

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

NCT ID: NCT07106762

This clinical trial is studying a new treatment called Izalontamab Brengitecan for people with advanced urothelial cancer, a type of bladder cancer that has spread to other parts of the body. The t...

Not yet recruiting

Phase: PHASE2 Conditions: Urothelial Cancer

Main Menu

Clinical Trials in Strasbourg, Alsace

38 Active Trials Found in Strasbourg

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy